NASDAQ:SLP

Simulations Plus Q4 2026 Earnings Results & Report

Simulations Plus logo
$18.50 0.00 (0.00%)
As of 11/6/2026

Simulations Plus was expected to report Q4 2026 earnings on October 29, 2026, after market closes. Analysts expected earnings of $0.09 per share on revenue of $17.44 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Earnings Announcement Details

Quarter
Q4 2026
Announcement Date
Time
After Market Closes

Simulations Plus EPS Results

Actual EPS
N/A
Consensus EPS
$0.09
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Simulations Plus Revenue Results

Actual Revenue
N/A
Expected Revenue
$17.44 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Simulations Plus Q4 2026 Earnings FAQ

Simulations Plus' next earnings date is estimated for Monday, December 7, 2026. MarketBeat tracks confirmed and estimated earnings dates for Simulations Plus on the company's earnings history page.

Simulations Plus Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Altaris Completes Acquisition of Simulations Plus
See More Simulations Plus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Simulations Plus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Simulations Plus and other key companies, straight to your email.

About Simulations Plus

Simulations Plus (NASDAQ:SLP) develops software and provides consulting services for the pharmaceutical and biotechnology industries. Its tools help researchers model how drugs behave in the body, assess drug properties, and support decisions during drug discovery and development.

The company’s products include GastroPlus for physiologically based pharmacokinetic modeling and simulation, ADMET Predictor for estimating absorption, distribution, metabolism, excretion and toxicity properties, and MonolixSuite for pharmacometrics and quantitative pharmacology. Simulations Plus also offers consulting in areas such as drug development modeling, regulatory strategy and data analysis.

Founded in 1996, Simulations Plus serves pharmaceutical and biotechnology companies, academic researchers and regulatory organizations in the United States and internationally. Its software and services are used across multiple stages of drug development, from early research through clinical development.

View Simulations Plus Profile